semaglutide liraglutide tirzepatide American Obesity Association Guidelines Regarding Role of 1. 2. 3. In management of Obesity and Percentage weight loss with These drugs. Improvement in Obesity related Co-morbids with these treatments liraglutide compared to tirzepatide A

These changes include: Declining estrogen levels that promote visceral fat accumulation Accelerated loss of fat-free mass Approximately 2-3% decline in resting metabolic rate per decade after age 20 Disrupted sleep patterns that further impair metabolism GLP-1 receptor agonists offer a particularly compelling approach for addressing menopause-related weight challenges by: Directly targeting the visceral adiposity that characterizes menopausal weight gain Countering metabolic slowdown through enhanced satiety signals Improving insulin sensitivity and glucose metabolism Potentially complementing hormone replacement therapy (HRT) The relationship between GLP-1RAs and HRT deserves special attention

We can do it together

People with mental health conditions that may be made worse by GLP-1s may also want to avoid taking the medication

Our patients love the results, and our treatments are backed by years of experience and research

This indicates that maternal AFB1 exposure can impair intestinal barrier homeostasis in offspring, reducing their capacity to tackle intestinal pathogens (Bastos-Amador et al